Liu Jiale, Wang Tao, Yang Fuyuan, Pubu Ciren
Department of Anaesthesiology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
School of Basic Medicine, Yangtze University Health Science Center, Jingzhou, Hubei, China.
Front Endocrinol (Lausanne). 2025 Sep 3;16:1642436. doi: 10.3389/fendo.2025.1642436. eCollection 2025.
As lifestyle patterns change, the rates of type 2 diabetes and obesity are increasing together, leading to an increase in metabolic-associated fatty liver disease (MAFLD), now recognized as the most frequently occurring liver disease globally. MAFLD presents a significant threat to public health and imposes a substantial socioeconomic burden. This condition encompasses a spectrum of hepatic manifestations, beginning with excessive fat accumulation and hepatic steatosis, and possibly progressing to non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and liver cancer. The pathogenesis of MAFLD is intricately linked to lipid accumulation, oxidative stress, and lipotoxicity. Notably, the interleukin-6 (IL-6) cytokine family plays a complex role in the onset and development of MAFLD, primarily through the modulation of lipid metabolism, insulin resistance, inflammatory responses, and liver fibrosis. This review examines the impact of the IL-6 family on the progression of MAFLD. It explores targeting the IL-6 family as a potential future therapy for MAFLD.
随着生活方式的改变，2型糖尿病和肥胖症的发病率同步上升，导致代谢相关脂肪性肝病（MAFLD）增加，该病现已被公认为全球最常见的肝脏疾病。MAFLD对公众健康构成重大威胁，并带来巨大的社会经济负担。这种疾病包括一系列肝脏表现，始于脂肪过度积累和肝脂肪变性，并可能进展为非酒精性脂肪性肝炎（NASH）、肝纤维化、肝硬化和肝癌。MAFLD的发病机制与脂质积累、氧化应激和脂毒性密切相关。值得注意的是，白细胞介素-6（IL-6）细胞因子家族在MAFLD的发生和发展中起复杂作用，主要通过调节脂质代谢、胰岛素抵抗、炎症反应和肝纤维化来实现。本综述探讨了IL-6家族对MAFLD进展的影响。它探讨了将靶向IL-6家族作为MAFLD未来潜在治疗方法的可能性。
